Intellego Technologies Reports Strong Q1 Performance

Intellego Technologies AB has reported a robust start to the financial year, with Q1 sales at SEK 200.9 million, marking a 152.5% increase year-over-year. This performance exceeded expectations and was bolstered by significant growth in North America and Asia, driven by strong dosimeter and YUVIO device sales. Major collaborations with Likang and Henkel have contributed to this success, suggesting promising potential for further growth.

The company achieved an EBIT of SEK 131.3 million, with a gross margin of 79.8%, surpassing initial forecasts. While operating cash flow decreased to SEK 28.3 million due to increased CAPEX, improved Days Sales Outstanding indicates better working capital management. Intellego's cash reserves at the quarter's end were SEK 3.8 million, with SEK 76.6 million available in unused credit lines, ensuring liquidity for continued expansion.

Intellego has raised its 2025 outlook, forecasting sales over SEK 600 million and EBIT surpassing SEK 250 million, citing sustained momentum. Long-term sales goals have been revisited, with the market potential now seen as much larger. Despite these ambitions, a detailed roadmap is needed for further outlook adjustments. The revised target price for the stock is SEK 125.00, maintaining a 'Buy' recommendation due to prospective growth.